Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

Ear2MemoryFree App | Free PDF | Web
Learning languages on your smartphone
By BSK

Free Abstracts

  Schizophrenia

  Free Subscription


Articles published in Neuropsychopharmacology

Retrieve available abstracts of 40 articles:
HTML format
Text format



Single Articles


    March 2017
  1. SARPAL DK, Robinson DG, Fales C, Lencz T, et al
    Relationship between Duration of Untreated Psychosis and Intrinsic Corticostriatal Connectivity in Patients with Early Phase Schizophrenia.
    Neuropsychopharmacology. 2017 Mar 15. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  2. POGORELOV VM, Rodriguiz RM, Cheng J, Huang M, et al
    5-HT2C Agonists Modulate Schizophrenia-Like Behaviors in Mice.
    Neuropsychopharmacology. 2017 Mar 15. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    February 2017
  3. ZHEUTLIN AB, Jeffries CD, Perkins DO, Chung Y, et al
    The Role of microRNA Expression in Cortical Development During Conversion to Psychosis.
    Neuropsychopharmacology. 2017 Feb 10. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    January 2017
  4. PEREZ VB, Tarasenko M, Miyakoshi M, Pianka ST, et al
    Mismatch Negativity is a Sensitive and Predictive Biomarker of Perceptual Learning During Auditory Cognitive Training in Schizophrenia.
    Neuropsychopharmacology. 2017 Jan 31. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


  5. HO NF, Holt DJ, Cheung M, Iglesias JE, et al
    Progressive Decline in Hippocampal CA1 Volume in Individuals at Ultra-High-Risk for Psychosis Who do not Remit: Findings from the Longitudinal Youth at Risk Study.
    Neuropsychopharmacology. 2017 Jan 12. doi: 10.1038/npp.2017.
    PubMed     Text format     Abstract available


    December 2016
  6. PETIT EI, Michalak Z, Cox R, O'Tuathaigh CM, et al
    Dysregulation of Specialized Delay/Interference-Dependent Working Memory Following Loss of Dysbindin-1A in Schizophrenia-Related Phenotypes.
    Neuropsychopharmacology. 2016 Dec 16. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  7. YOUNG JW, Bismark AW, Sun Y, Zhang W, et al
    Neurophysiological Characterization of Attentional Performance Dysfunction in Schizophrenia Patients in a Reverse-Translated Task.
    Neuropsychopharmacology. 2016 Dec 5. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    November 2016
  8. KIM E, Howes OD, Veronese M, Beck K, et al
    Presynaptic Dopamine Capacity in Patients with Treatment Resistant Schizophrenia Taking Clozapine: An [18F]DOPA PET Study.
    Neuropsychopharmacology. 2016 Nov 18. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    October 2016
  9. GONG Q, Hu X, Pettersson-Yeo W, Xu X, et al
    Network-Level Dysconnectivity in Drug-Naive First Episode Psychosis: Dissociating Trans-Diagnostic and Diagnosis-Specific Alterations.
    Neuropsychopharmacology. 2016 Oct 26. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    September 2016
  10. MILLER BJ, Goldsmith DR
    Towards an Immunophenotype of Schizophrenia: Progress, Potential Mechanisms, and Future Directions.
    Neuropsychopharmacology. 2016 Sep 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    August 2016
  11. WIJTENBURG SA, Wright SN, Korenic SA, Gaston FE, et al
    Altered Glutamate and Regional Cerebral Blood Flow Levels in Schizophrenia: A 1H-MRS and pCASL Study.
    Neuropsychopharmacology. 2016 Aug 26. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  12. SCHOONOVER KE, McCollum LA, Roberts RC
    Protein Markers of Neurotransmitter Synthesis and Release in Postmortem Schizophrenia Substantia Nigra.
    Neuropsychopharmacology. 2016 Aug 23. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    July 2016
  13. DE LEEUW M, Bohlken MM, Mandl RC, Hillegers MH, et al
    Changes in White Matter Organization in Adolescent Offspring of Schizophrenia Patients.
    Neuropsychopharmacology. 2016 Jul 21. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    June 2016
  14. HAIG G, Wang D, Othman AA, Zhao J, et al
    The alpha7 Nicotinic Agonist ABT-126 in the Treatment of Cognitive Impairment Associated with Schizophrenia in Nonsmokers: Results from a Randomized Controlled Phase 2b Study.
    Neuropsychopharmacology. 2016 Jun 20. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  15. PLITMAN E, Patel R, Chung JK, Pipitone J, et al
    Glutamatergic Metabolites, Volume and Cortical Thickness in Antipsychotic-Naive Patients with First-Episode Psychosis: Implications for Excitotoxicity.
    Neuropsychopharmacology. 2016 Jun 8. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    May 2016
  16. CHIAPPELLI J, Postolache TT, Kochunov P, Rowland LM, et al
    Tryptophan Metabolism and White Matter Integrity in Schizophrenia.
    Neuropsychopharmacology. 2016 May 4. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    April 2016
  17. ERYILMAZ H, Tanner AS, Ho NF, Nitenson AZ, et al
    Disrupted working Memory Circuitry in Schizophrenia: Disentangling fMRI Markers of Core Pathology Versus other Aspects of Impaired Performance.
    Neuropsychopharmacology. 2016 Apr 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  18. SCHWEHM A, Robinson DG, Gallego JA, Karlsgodt KH, et al
    Age and Sex Effects on White Matter Tracts in Psychosis from Adolescence though Middle Adulthood.
    Neuropsychopharmacology. 2016 Apr 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  19. FRYER SL, Roach BJ, Wiley K, Loewy RL, et al
    Reduced Amplitude of Low-Frequency Brain Oscillations in the Psychosis Risk Syndrome and Early Illness Schizophrenia.
    Neuropsychopharmacology. 2016 Apr 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  20. GOONAWARDENA AV, Heiss J, Glavis-Bloom C, Trube G, et al
    Alterations in High-Frequency Neuronal Oscillations in a Cynomolgus Macaque Test of Sustained Attention Following NMDA Receptor Antagonism.
    Neuropsychopharmacology. 2016;41:1319-28.
    PubMed     Text format     Abstract available


    March 2016
  21. DU Y, Grace AA
    Amygdala Hyperactivity in MAM Model of Schizophrenia is Normalized by Peripubertal Diazepam Administration.
    Neuropsychopharmacology. 2016 Mar 22. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  22. CASTRO VM, Roberson AM, McCoy TH, Wiste A, et al
    Stratifying Risk for Renal Insufficiency Among Lithium-Treated Patients: An Electronic Health Record Study.
    Neuropsychopharmacology. 2016;41:1138-43.
    PubMed     Text format     Abstract available


    February 2016
  23. ENWRIGHT JF, Sanapala S, Foglio A, Berry R, et al
    Reduced Labeling of Parvalbumin Neurons and Perineuronal Nets in the Dorsolateral Prefrontal Cortex of Subjects with Schizophrenia.
    Neuropsychopharmacology. 2016 Feb 12. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


    January 2016
  24. BALU DT, Li Y, Takagi S, Presti KT, et al
    An mGlu5 Positive Allosteric Modulator Rescues the Neuroplasticity Deficits in a Genetic Model of NMDA Receptor Hypofunction in Schizophrenia.
    Neuropsychopharmacology. 2016 Jan 7. doi: 10.1038/npp.2016.
    PubMed     Text format     Abstract available


  25. WEICKERT CS, Weickert TW
    Hormone modulation improves cognition in schizophrenia.
    Neuropsychopharmacology. 2016;41:384-5.
    PubMed     Text format    


    December 2015
  26. SEGARRA N, Metastasio A, Ziauddeen H, Spencer J, et al
    Abnormal Frontostriatal Activity during Unexpected Reward Receipt in Depression and Schizophrenia: Relationship to Anhedonia.
    Neuropsychopharmacology. 2015 Dec 28. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


    October 2015
  27. DEAN B, Hopper S, Conn PJ, Scarr E, et al
    Changes in BQCA Allosteric Modulation of [H]NMS Binding to Human Cortex within Schizophrenia and by Divalent Cations.
    Neuropsychopharmacology. 2015 Oct 29. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


    September 2015
  28. COLIBAZZI T, Horga G, Wang Z, Huo Y, et al
    Neural Dysfunction in Cognitive Control Circuits in Persons at Clinical High-Risk for Psychosis.
    Neuropsychopharmacology. 2015 Sep 10. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  29. MIZRAHI R
    Social Stress and Psychosis Risk: Common Neurochemical Substrates?
    Neuropsychopharmacology. 2015 Sep 7. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  30. WHITE TP, Wigton R, Joyce DW, Collier T, et al
    Dysfunctional Striatal Systems in Treatment-Resistant Schizophrenia.
    Neuropsychopharmacology. 2015 Sep 7. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  31. MINZENBERG MJ, Yoon JH, Cheng Y, Carter CS, et al
    Sustained Modafinil Treatment Effects on Control-Related Gamma Oscillatory Power in Schizophrenia.
    Neuropsychopharmacology. 2015 Sep 2. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


    August 2015
  32. SHIN NY, Park HY, Jung WH, Park JW, et al
    Effects of Oxytocin on Neural Response to Facial Expressions in Patients with Schizophrenia.
    Neuropsychopharmacology. 2015;40:2286.
    PubMed     Text format    


    July 2015
  33. VITUCCI D, Di Giorgio A, Napolitano F, Pelosi B, et al
    Rasd2 Modulates Prefronto-Striatal Phenotypes in Humans and "Schizophrenia-Like Behaviors" in Mice.
    Neuropsychopharmacology. 2015 Jul 31. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  34. SCOTT MR, Rubio MD, Haroutunian V, Meador-Woodruff JH, et al
    Protein Expression of Proteasome Subunits in Elderly Patients With Schizophrenia.
    Neuropsychopharmacology. 2015 Jul 23. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  35. PARK SM, Chen M, Schmerberg CM, Dulman RS, et al
    Effects of beta-Arrestin-Biased Dopamine D2 Receptor Ligands on Schizophrenia-like Behavior in Hypoglutamatergic Mice.
    Neuropsychopharmacology. 2015 Jul 1. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


    June 2015
  36. GHOSHAL A, Rook JM, Dickerson JW, Roop GN, et al
    Potentiation of M Muscarinic Receptor Reverses Plasticity Deficits and Negative and Cognitive Symptoms in a Schizophrenia Mouse Model.
    Neuropsychopharmacology. 2015 Jun 25. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  37. KEEFE RS, Meltzer HA, Dgetluck N, Gawryl M, et al
    Randomized, Double-Blind, Placebo-Controlled Study of Encenicline, an Alpha-7 Nicotinic Acetylcholine Receptor Agonist as a Treatment for Cognitive Impairment in Schizophrenia.
    Neuropsychopharmacology. 2015 Jun 19. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  38. PEREZ SM, Aguilar DA, Neary JL, Carless MA, et al
    Schizophrenia-Like Phenotype Inherited by the F2 Generation of a Gestational Disruption Model of Schizophrenia.
    Neuropsychopharmacology. 2015 Jun 12. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  39. DENG QS, Dong XY, Wu H, Wang W, et al
    Disrupted-in-Schizophrenia-1 Attenuates Amyloid-beta Generation and Cognitive Deficits in APP/PS1 Transgenic Mice by Reduction of beta-site APP-Cleaving Enzyme 1 Levels.
    Neuropsychopharmacology. 2015 Jun 11. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


  40. SWERDLOW NR, Bhakta S, Chou HH, Talledo JA, et al
    Memantine Effects on Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.
    Neuropsychopharmacology. 2015 Jun 11. doi: 10.1038/npp.2015.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Schizophrenia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: